Fate Therapeutics, Inc. - stock earnings
FATE Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 AfterMarket | -0.45 / -0.50 | - | - / 1.1 million | - |
FATE Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -44.1 million USD | 1.7 million USD |
| 2023Q3 | -45.2 million USD | 1.9 million USD |
| 2023Q2 | -52.8 million USD | 933000 USD |
| 2023Q1 | -9.2 million USD | 59.0 million USD |
| 2022Q4 | -48.3 million USD | 44.4 million USD |
| 2022Q3 | -80.7 million USD | 15.0 million USD |
| 2022Q2 | -69.1 million USD | 18.5 million USD |
| 2022Q1 | -56.9 million USD | 18.4 million USD |
| 2021Q4 | -68.6 million USD | 17.1 million USD |
| 2021Q3 | -43.3 million USD | 14.2 million USD |
| 2021Q2 | -55.1 million USD | 13.4 million USD |
| 2021Q1 | -45.1 million USD | 11.1 million USD |
| 2020Q4 | -53.1 million USD | 15.9 million USD |
| 2020Q3 | -58.7 million USD | 7.6 million USD |
| 2020Q2 | -28.1 million USD | 5.5 million USD |
| 2020Q1 | -33.5 million USD | 2.5 million USD |
| 2019Q4 | -28.3 million USD | 2.8 million USD |
| 2019Q3 | -26.6 million USD | 2.4 million USD |
| 2019Q2 | -23.5 million USD | 2.8 million USD |
| 2019Q1 | -19.8 million USD | 2.6 million USD |
| 2018Q4 | -16.0 million USD | 1.7 million USD |
| 2018Q3 | -16.8 million USD | 1.0 million USD |
| 2018Q2 | -19.7 million USD | 1.0 million USD |
| 2018Q1 | -14.1 million USD | 1.0 million USD |
| 2017Q4 | -12.5 million USD | 1.0 million USD |
| 2017Q3 | -10.7 million USD | 1.0 million USD |
| 2017Q2 | -9.6 million USD | 1.0 million USD |
| 2017Q1 | -10.1 million USD | 1.0 million USD |
| 2016Q4 | -7.9 million USD | 1.0 million USD |
| 2016Q3 | -8.7 million USD | 1.0 million USD |
| 2016Q2 | -8.4 million USD | 1.0 million USD |
| 2016Q1 | -8.4 million USD | 1.3 million USD |
| 2015Q4 | -7.4 million USD | 1.1 million USD |
| 2015Q3 | -6.9 million USD | 1.0 million USD |
| 2015Q2 | -7.8 million USD | 329000 USD |
| 2015Q1 | -7.9 million USD | ? USD |
| 2014Q4 | -6.2 million USD | ? USD |
| 2014Q3 | -6.6 million USD | ? USD |
| 2014Q2 | -6.1 million USD | ? USD |
| 2014Q1 | -7.0 million USD | ? USD |
| 2013Q4 | -5.7 million USD | -971000 USD |
| 2013Q3 | -6.1 million USD | 209000 USD |
| 2013Q2 | -5.5 million USD | 290000 USD |
| 2013Q1 | -3.5 million USD | 472000 USD |
| 2012Q4 | -4.2 million USD | 643000 USD |
| 2012Q3 | -4.1 million USD | 528000 USD |
| 2012Q2 | ? USD | 1.5 million USD |
| 2011Q4 | ? USD | 1.2 million USD |
FATE Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -160.9 million USD | 63.5 million USD |
| 2022 | -255.1 million USD | 96.3 million USD |
| 2021 | -206.3 million USD | 55.8 million USD |
| 2020 | -170.3 million USD | 31.4 million USD |
| 2019 | -97.7 million USD | 10.7 million USD |
| 2018 | -66.6 million USD | 4.7 million USD |
| 2017 | -43.0 million USD | 4.1 million USD |
| 2016 | -33.5 million USD | 4.4 million USD |
| 2015 | -30.0 million USD | 2.4 million USD |
| 2014 | -25.9 million USD | ? USD |
| 2013 | -20.9 million USD | 971000 USD |
| 2012 | -14.2 million USD | 2.7 million USD |
| 2011 | -13.4 million USD | 1.2 million USD |
FATE
Price: $4.07
52 week price:
Earnings Per Share: -1.64 USD
P/E Ratio: -3.92
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.6 million
Ebitda: -10.1 millionMarket Capitalization: 465.4 million